Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: Evaluation of new 6-desfluoroquinolone derivatives

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1407-1413

  Stevens, Miguel ^a   Pollicita, Michela ^e   Pannecouque, Christophe ^a   Verbeken, Erik ^b   Tabarrini, Oriana ^c   Cecchetti, Violetta ^c   Aquaro, Stefano ^d,e   Perno, Carlo Federico ^e   Fravolini, Arnaldo ^c   De Clercq, Erik ^a   Schols, Dominique ^a   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF CALABRIA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HM 12; HM 13; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TR 87; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; DOSE RESPONSE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INFECTION CONTROL; LATENT VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; VIRUS REACTIVATION; VIRUS TRANSCRIPTION;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, SCID; MODELS, BIOLOGICAL; QUINOLONES;

EID: 34247140849     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01251-06     Document Type: Article

References (48)

1. Aquaro, S., P. Menten, S. Struyf, P. Proost, J. Van Damme, E. De Clercq, and D. Schols. 2001. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages. J. Virol. 75:4402-4406.
2. Aquaro, S., and C. F. Perno. 2005. Assessing the relative efficacy of antiretroviral activity of different drugs on macrophages, p. 445-453. In T. Zhu (ed.), Human retrovirus protocols. Human Press, Totowa, NJ.
3. Arten, P. A., D. G. Brooks, L. Y. Gao, D. Vatakis, H. J. Brown, and J. A. Zack. 2006. Rapid expression of human immunodeficiency virus following activation of latently infected cells. J. Virol. 80:1599-1603.
4. Baba, M., M. Okamoto, M. Makino, Y. Kimura, T. Ikeuchi, T. Sakaguchi, and T. Okamoto. 1997. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 41:1250-1255.
5. Baba, M., M. Okamoto, M. Kawamura, M. Makino, T. Higashida, T. Takashi, Y. Kimura, T. Ikeuchi, T. Tetsuka, and T. Okamoto. 1998. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol. 53:1097-1103.
6. -/- mice. Proc. Natl. Acad. Sci. USA 103:15951-15956.
7. -/- (RAG-hu) mouse model. Retrovirology 3:76.
8. Bohjanen, P. R., R. A. Colvin, M. Puttaraju, M. D. Been, and M. A. Garcia-Blanco. 1996. A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. Nucleic Acids Res. 24:3733-3738.
9. Brooks, D. G., D. H. Hamer, P. A. Arlen, L. Gao, G. Bristol, C. M. R. Kitchen, E. A. Berger, and J. A. Zack. 2003. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19:413-423.
10. + cell model of chronic infection. J. Virol. 65:4645-4653.
11. Cecchetti, V., C. Parolin, S. Moro, T. Pecere, E. Filipponi, A. Calistri, O. Tabarrini, B. Gatto, M. Palumbo, A. Fravolini, and G. Palù. 2000. 6-Aminoquinolones as new potential anti-HIV agents. J. Med. Chem. 43:3799-3802.
12. Cenci, A., C. F. Perno, S. Menzo, M. Clementi, F. Erba, B. Tavazzi, D. Di Pierro, S. Aquaro, and R. Caliò. 1997. Selected nucleotide sequence of the pol gene of the monocytotropic strain HIV type 1 BaL. AIDS Res. Hum. Retrovir. 13:629-632.
13. Choudhury, I., J. Wang, A. B. Rabson, S. Stein, S. Pooyan, S. Stein, and M. J. Leibowitz. 1998. Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17:104-111.
14. Chun, T.-W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. M. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
15. Darfeuille, F., A. Arzumanov, M. J. Gait, C. Di Primo, and J. J. Toulme. 2002. 2′-O-Methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry 41:12186-12192.
16. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
17. Folks, T. M., J. Justement, A. Kinter, C. A. Dinarello, and A. S. Fauci. 1987. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238:800-802.
18. Gartner, S., P. Markovits, D. M. Markovits, M. H. Kaplan, R. C. Gallo, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215-219.
19. Hamy, F., E. R. Felder, G. Heizmann, J. Lazdins, F. Aboul-ela, G. Varani, J. Karn, and T. Klimkait. 1997. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl. Acad. Sci. USA 94:3548-3553.
20. + T lymphocytes in vivo. J. Virol. 77:7383-7392.
21. Hwang, S., N. Tamilarasu, K. Kibler, H. Cao, A. Ali, Y. H. Ping, K. T. Jeang, and T. M. Rana. 2003. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J. Biol. Chem. 278:39092-39103.
22. Kolb, G., S. Reigadas, C. Boiziau, A. van Aerschot, A. Arzumanov, M. J. Gait, P. Herdewijn, and J. J. Toulme. 2005. Hexitol nucleic acid-containing aptamers are efficient ligands of HIV-1 TAR RNA. Biochemistry 44:2926-2933.
23. + T cells in vivo. J. Virol. 78:9105-9114.
24. Lin, X., D. Irwin, S. Kanazawa, L. Huang, J. Romeo, T. S. Yen, and B. M. Peterlin. 2003. Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir. J. Virol. 77:8227-8236.
25. Litovchick, A., A. G. Evdokimov, and A. Lapidot. 1999. Arginine-aminoglycoside conjugates that bind to HIV transactivation responsive element RNA in vitro. FEBS Lett. 445:73-79.
26. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
27. Mayhood, T., N. Kaushik, P. K. Pandey, F. Kashanchi, L. Deng, and V. N. Pandey. 2000. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element. Biochemistry 39:11532-11539.
28. McCune, J., H. Kaneshima, J. Krowka, R. Namikawa, H. Outzen, B. Peault, L. Rabin, C. C. Shih, and E. Yee. 1991. The SCID-hu mouse: a small animal model for HIV infection and pathogenesis. Annu. Rev. Immunol. 9:399-429.
29. Michienzi, A., S. Li, J. A. Zaia, and J. J. Rossi. 2002. A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc. Natl. Acad. Sci. USA 99:14047-14052.
30. Mosier, D. E., R. J. Gulizia, S. M. Baird, D. B. Wilson, D. H. Spector, and S. A. Spector. 1991. Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251:791-794.
31. Mosier, D. E. 1996. Viral pathogenesis in hu-PBL-SCID mice. Semin. Immunol. 8:255-262.
32. Murchie, A. I., B. Davis, C. Isel, M. Afshar, M. J. Drysdale, J. Bower, A. J. Potter, I. D. Starkey, T. M. Swarbrick, S. Mirza, C. D. Prescott, P. Vaglio, F. Aboul-ela, and J. Karn. 2004. Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA. J. Mol. Biol. 336:625-638.
33. Namikawa, R., H. Kaneshima, M. Lieberman, I. L. Weissman, and J. M. McCune. 1988. Infection of the SCID-hu mouse by HIV-1. Science 242:1684-1686.
34. Parolin, C., B. Gatto, C. Del Vecchio, T. Pecere, E. Tramontano, V. Cecchetti, A. Fravolini, S. Masiero, M. Palumbo, and G. Palu. 2003. New anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action. Antimicrob. Agents Chemother. 47:889-896.
35. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
36. Perno, C. F., A. Bergamini, C. D. Pesce, G. Milanese, M. Capozzi, S. Aquaro, S. Thaisrivongs, W. G. Tarpley, G. Zon, C. D'Agostini, G. Rocchi, E. Garaci, and R. Caliò. 1993. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. J. Infect. Dis. 168:1148-1156.
37. Popovic, M., M. G. Sarnagadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
38. Richter, S., C. Parolin, B. Gatto, C. Del Vecchio, E. Brocca-Cofano, A. Fravolini, G. Palù, and M. Palumbo. 2004. Inhibition of human immunodeficiency virus type 1 Tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob. Agents Chemother. 48:1895-1899.
39. Richter, S., C. Parolin, M. Palumbo, and G. Palù. 2004. Antiviral properties of quinolone-based drugs. Curr. Drug Targets Infect. Disord. 4:111-116.
40. Richter, S., B. Gatto, O. Tabarrini, A. Fravolini, and M. Palumbo. 2005. Antiviral 6-amino-quinolones: molecular basis for potency and selectivity. Bioorg. Med. Chem. Lett. 15:4247-4251.
41. Stevens, M., J. Balzarini, O. Tabarrini, G. Andrei, R. Snoeck, V. Cecchetti, A. Fravolini, E. De Clercq, and C. Pannecouque. 2005. Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. J. Antimicrob. Chemother. 56:847-855.
42. Stevens, M., E. De Clercq, and J. Balzarini. 2006. The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med. Res. Rev. 26:595-625.
43. Sullenger, B. A., H. F. Gallardo, G. E. Ungers, and E. Gilboa. 1991. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J. Virol. 65:6811-6816.
44. Tabarrini, O., M. Stevens, V. Cecchetti, S. Sabatini, M. Dell'Uomo, G. Manfroni, M. Palumbo, C. Pannecouque, E. De Clercq, and A. Fravolini. 2004. Structure modifications of 6-aminoquinolones with potent anti-HIV activity. J. Med. Chem. 47:5567-5578.
45. Tabarrini, O., G. Manfroni, M. Stevens, S. Sabatini, V. Cecchetti, S. Massari, C. Pannecouque, E. De Clercq, and A. Fravolini. 2005. Studies on anti-HIV quinolones, p. 46. Second Joint Italian-Swiss Meet. Med. Chem., Modena, Italy, September 2005.
46. Witvrouw, M., D. Daelemans, C. Pannecouque, J. Neyts, G. Andrei, R. Snoeck, A. M. Vandamme, J. Balzarini, J. Desmyter, M. Baba, and E. De Clercq. 1998. Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12. Antivir. Chem. Chemother. 9:403-411.
47. Wong, J. K., M. Hezareh, H. F. Günthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
48. Zhang, L., G. I. Kovalev, and L. Su. 28 November 2006. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood doi:10.1182/blood-2006-07-033159.